The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

Kevin R. Kelly, Jeffrey Ecsedy, Ernest Medina, Devalingam Mahalingam, Swaminathan Padmanabhan, Steffan T. Nawrocki, Francis J. Giles, Jennifer S. Carew*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Fingerprint

Dive into the research topics of 'The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib'. Together they form a unique fingerprint.

Medicine & Life Sciences